Evidence map›Paper›PMID 38267716›Full record

ArticleNature reviews. Urology2024

Pembrolizumab plus enfortumab vedotin in urothelial cancer.

Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt

Abstract read
PubMed Publisher
In one paragraph

Article in Nature reviews. Urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matteo SantoniOncology Unit, Macerata Hospital, Macerata, Italy.
Hideki TakeshitaDepartment of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.ORCID 0000-0002-1512-6904
Francesco MassariMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. fmassari79@gmail.com.ORCID 0000-0001-6476-6871
Aristotelis Bamias2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Linda CerboneDepartment of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
Ondrej FialaDepartment of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
Veronica MollicaMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Sebastiano ButiMedical Oncology Unit, University Hospital of Parma - Department of Medicin and Surgery, University of Parma, Parma, Italy.ORCID 0000-0003-0876-0226
Angela SantoniDepartment of Molecular Medicine, Sapienza University, Rome Italian Pasteur Institute, Cenci-Bolognetti Foundation, Rome, Italy.
Joaquim BellmuntDana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2328-3421

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCarcinoma, Transitional CellUrinary Bladder NeoplasmsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsHumansUrologic NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalenfortumab vedotinpembrolizumab

Identifiers

PMID38267716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.